What you need to know
Hackensack University Medical Center performed its first cardiovascular surgery procedures using a new heart pump called the Impella 5.5 with SmartAssist.
Hackensack University Medical Center is one of only three hospitals in the country that currently has access to this new technology, and the first hospital in the U.S. to successfully perform procedures using the device.
The Impella 5.5 is being introduced in the U.S. through a controlled rollout at select hospitals with established heart recovery protocols. Hackensack University Medical Center is the only hospital in the northeastern U.S. that is participating in this controlled rollout.
The Impella 5.5 recently received pre-market approval (PMA) from the U.S. Food and Drug Administration (FDA) for the treatment of cardiogenic shock.
Cardiogenic shock is a serious condition that occurs when a patient’s heart is unable to pump enough blood to meet his or her body’s needs. Cardiogenic shock can happen after a heart attack or open heart surgery, or result from a condition called cardiomyopathy.
The Impella 5.5 device — which is a short-term left ventricular assist device (LVAD) — temporarily takes over the pumping function of the heart and can be used for up to 14 days, ensuring that the heart can still pump enough blood for the body while reducing strain on the heart during recovery.
To date, four patients have received the Impella 5.5 at Hackensack University Medical Center. They are recovering as expected following the procedure. Hackensack University Medical Center physicians said that the Impella 5.5 was the “best option” to promote each patient’s recovery after cardiogenic shock.
About the Impella 5.5
The Impella 5.5 has been designed to be inserted into the left ventricle of the heart through either the axillary artery or directly into the anterior aorta during a minimally invasive, catheter-based procedure called percutaneous coronary intervention (PCI). Because the Impella 5.5 can be placed through axillary vein catheterization, inserted through a small incision in a patient’s chest, it eliminates the need for opening the chest during an invasive sternotomy or performing another procedure called left ventricle coring which can create problematic scarring.
In addition to providing surgeons with a minimally invasive solution to maintain blood flow while allowing the heart to recover, the new device has several advantages, including:
- Forward flow design, meaning that it effectively pumps blood at a peak flow of greater than 6 liters per minute and maintains blood supply to vital organs
- Fully unloading design, which means that it reduces the work and oxygen demands placed on the heart
- A thinner, shorter motor housing than previous Impella models and a fiber optic pressure sensor, which allows for easier pump insertion and precise positioning
- SmartAssist technology that provides data such as left ventricular pressure (LVP), end-diastolic pressure (EDP), and cardiac power output (CPO) to help physicians make critical patient-care decisions
- Impella Connect, which allows clinicians to securely and remotely monitor patient data collected by the pump 24/7, through any internet-connected device
The Impella 5.5 also provides improved patient mobility, allowing patients to get up and walk around after the device is in place — promoting faster healing and speeding the recovery process.